scholarly article | Q13442814 |
P356 | DOI | 10.3324/HAEMATOL.2015.135699 |
P8608 | Fatcat ID | release_eplmm3lvjzc45ckefwgd7v32ay |
P932 | PMC publication ID | 4938329 |
P698 | PubMed publication ID | 26565001 |
P50 | author | Dietger Niederwieser | Q88402151 |
Myriam Labopin | Q89534568 | ||
Emmanuelle Polge | Q89534576 | ||
Arnon Nagler | Q89534579 | ||
Fabio Ciceri | Q90995474 | ||
Sebastian Giebel | Q92489652 | ||
Arnold Ganser | Q99412936 | ||
Rainer Schwerdtfeger | Q114426804 | ||
Stephane Vigouroux | Q114428271 | ||
Bipin N Savani | Q53683697 | ||
Noel Jean Milpied | Q55743774 | ||
Boris Afanasyev | Q60608189 | ||
Mohamad Mohty | Q86836425 | ||
Didier Blaise | Q88013295 | ||
P2093 | author name string | Michael Hallek | |
Jan J Cornelissen | |||
Frédéric Baron | |||
Christoph Schmid | |||
Jordi Esteve | |||
Renate Arnold | |||
Norbert C Gorin | |||
P2860 | cites work | Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults | Q24195048 |
Defining the intensity of conditioning regimens: working definitions | Q24630836 | ||
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission | Q34033852 | ||
High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation | Q34582448 | ||
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis | Q34620456 | ||
Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era | Q34749365 | ||
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy | Q34749391 | ||
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation | Q34996663 | ||
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial | Q34998580 | ||
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. | Q35288778 | ||
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q35571053 | ||
Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. | Q35800814 | ||
Peripheral-blood stem cells versus bone marrow from unrelated donors | Q37276359 | ||
Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease | Q37632798 | ||
Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation | Q38284507 | ||
Reduced-intensity conditioned allogeneic SCT in adults with AML. | Q38366632 | ||
1994 Consensus Conference on Acute GVHD Grading | Q39513397 | ||
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution | Q43001701 | ||
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the Europea | Q43992557 | ||
Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. | Q44275281 | ||
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies | Q44447834 | ||
Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis fro | Q45216935 | ||
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. | Q52905842 | ||
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial | Q74389035 | ||
Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study | Q78385763 | ||
Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working | Q84258632 | ||
P433 | issue | 2 | |
P921 | main subject | acute leukemia | Q976388 |
leukemia | Q29496 | ||
P304 | page(s) | 256-262 | |
P577 | publication date | 2015-11-12 | |
P1433 | published in | Haematologica | Q5638209 |
P1476 | title | Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. | |
P478 | volume | 101 |
Q52718440 | AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. |
Q90065178 | Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic progenitor cell mobilization in response to G-CSF |
Q37618811 | Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
Q94562861 | Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia |
Q94496786 | Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT |
Q39414681 | Cytokine Release Patterns in Mixed Lymphocyte Culture (MLC) of T-Cells with Dendritic Cells (DC) Generated from AML Blasts Contribute to Predict anti-Leukaemic T-Cell Reactions and Patients' Response to Immunotherapy |
Q58713268 | Early CD8+-recovery independently predicts low probability of disease relapse but also associates with severe GVHD after allogeneic HSCT |
Q48103108 | Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia. |
Q39031745 | Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy |
Q92757989 | Personalizing rabbit anti-thymocyte globulin therapy for prevention of graft-versus-host disease after allogeneic hematopoietic cell transplantation: is there an optimal dose? |
Q90325829 | Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients |
Q52584529 | Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. |
Q38863489 | Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. |
Q30240238 | Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens |
Q57158669 | Trends in peripheral stem/progenitor cell manipulation and clinical application |
Search more.